GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Ascentage Pharma Group International 6855.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

29.86

+1.98%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥652.2m

FY2016FY2025

Net income

−CN¥1.41bn

FY2016FY2025

Free cash flow

−CN¥1.40bn

FY2016FY2025

Shareholders' equity

CN¥1.55bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥652.2mCN¥980.6mCN¥222.0mCN¥209.7mCN¥32.5mCN¥12.4mCN¥14.5mCN¥6.8mCN¥6.3mCN¥7.7m
Research and developmentCN¥1.27bnCN¥947.2mCN¥707.0mCN¥743.1mCN¥893.9mCN¥564.6mCN¥463.9mCN¥249.6mCN¥118.8mCN¥102.7m
Operating income−CN¥1.38bn−CN¥378.8m−CN¥869.2m−CN¥883.4m−CN¥1.09bn−CN¥684.4m−CN¥613.1m−CN¥317.1m−CN¥98.3m−CN¥117.6m
Net income−CN¥1.41bn−CN¥405.4m−CN¥925.6m−CN¥882.9m−CN¥912.4m−CN¥677.6m−CN¥1.48bn−CN¥345.3m−CN¥118.5m−CN¥107.8m
Diluted earnings per share-3.81-1.30-3.19-3.35-3.48-3.00-10.88-2.96-0.57-0.52

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥4.62bnCN¥3.05bnCN¥2.92bnCN¥3.30bnCN¥3.43bnCN¥1.73bnCN¥1.21bnCN¥1.23bnCN¥581.7mCN¥593.3m
Cash and short-term investmentsCN¥2.88bnCN¥1.47bnCN¥1.28bnCN¥1.75bnCN¥2.04bnCN¥1.02bnCN¥885.1mCN¥971.5mCN¥399.0mCN¥451.9m
Total liabilitiesCN¥3.07bnCN¥2.73bnCN¥2.83bnCN¥2.82bnCN¥1.99bnCN¥884.4mCN¥314.6mCN¥2.24bnCN¥713.5mCN¥607.9m
DebtCN¥2.32bnCN¥1.67bnCN¥1.80bnCN¥1.79bnCN¥1.08bnCN¥529.7mCN¥101.4mCN¥2.12bnCN¥4.9mCN¥830,000
Shareholders' equityCN¥1.55bnCN¥308.1mCN¥70.5mCN¥476.6mCN¥1.44bnCN¥846.6mCN¥890.5m−CN¥1.01bn−CN¥131.8m−CN¥14.6m
Shares outstanding370m312m290m264m262m226m136m117m207m207m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−CN¥1.37bn−CN¥111.4m−CN¥846.7m−CN¥762.6m−CN¥705.2m−CN¥610.0m−CN¥460.3m−CN¥237.7m−CN¥108.0m−CN¥45.9m
Capital spending−CN¥32.2m−CN¥24.3m−CN¥66.3m−CN¥237.1m−CN¥507.8m−CN¥249.9m−CN¥77.5m−CN¥49.5m−CN¥20.5m−CN¥3.4m
Free cash flow−CN¥1.40bn−CN¥135.6m−CN¥913.0m−CN¥999.7m−CN¥1.21bn−CN¥859.9m−CN¥537.8m−CN¥287.1m−CN¥128.5m−CN¥49.3m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Mar 2023
RevenueCN¥347.6mCN¥390.4mCN¥272.5mCN¥156.9mCN¥823.7mCN¥79.3mCN¥142.7mCN¥71.3m
Operating income−CN¥865.2m−CN¥748.7m−CN¥646.0m−CN¥566.8mCN¥188.0m−CN¥532.1m−CN¥359.9m−CN¥206.3m
Net income−CN¥939.3m−CN¥747.7m−CN¥688.9m−CN¥568.4mCN¥163.0m−CN¥523.3m−CN¥402.4m−CN¥201.2m
Diluted earnings per share-2.52-2.02-1.86-1.820.52-1.80-1.39-0.73
Cash from operations−CN¥698.0m−CN¥911.0m−CN¥503.0mCN¥243.0m−CN¥354.0m−CN¥417.0m−CN¥429.0m−CN¥214.0m
Capital spending−CN¥13.0m−CN¥9.0m−CN¥23.0m−CN¥7.0m−CN¥16.0m−CN¥14.0m−CN¥39.0m−CN¥19.0m
Free cash flow−CN¥711.0m−CN¥920.0m−CN¥526.0mCN¥236.0m−CN¥370.0m−CN¥431.0m−CN¥468.0m−CN¥233.0m
Total assetsCN¥3.78bnCN¥4.62bnCN¥3.55bnCN¥2.62bnCN¥3.11bnCN¥2.50bnCN¥3.40bn—
Cash and short-term investmentsCN¥2.21bnCN¥2.88bnCN¥1.94bnCN¥1.26bnCN¥1.10bnCN¥1.10bnCN¥1.84bn—
DebtCN¥1.72bnCN¥2.32bnCN¥2.00bnCN¥1.67bnCN¥1.70bnCN¥1.80bnCN¥1.95bn—
Shareholders' equityCN¥648.7mCN¥1.55bnCN¥776.7mCN¥264.2mCN¥766.4mCN¥60.4mCN¥687.9m—

Financial ratios

Data as of 30 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-211.1%-38.6%-391.6%-421.2%-3343.5%-5497.4%
Net margin-216.5%-41.3%-417.0%-421.0%-2803.4%-5442.6%
Return on equity-91.4%-153.5%-1532.1%-216.1%-63.4%-80.0%
Return on assets-30.5%-15.5%-37.0%-31.2%-26.6%-39.1%
Free cash flow yield-10.0%-0.9%-7.5%-5.5%-2.1%-5.2%
Revenue growth-43.0%341.8%5.9%651.4%124.2%-14.2%
Earnings growth198.6%-56.2%4.8%12.8%15.5%-54.2%
Current ratio1.79x1.26x1.44x1.86x5.22x3.91x
Debt to equity1.49x6.24x29.51x4.36x0.87x0.61x
Equity ratio33.4%10.1%2.4%14.4%42.0%48.9%
Interest coverage-22.42x-5.88x-9.05x-16.74x-55.77x-109.42x
R&D as a share of sales194.0%96.6%318.5%354.3%2746.3%4534.7%
Buybacks as a share of market value-18.6%-7.7%-10.0%-0.6%-16.0%-66.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue46.0%120.7%—
Operating income15.9%15.0%—
Net income16.9%15.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-11.9-30.4-7.4-6.7-7.0-11.3-2.4
Price to sales25.912.630.928.0196.8—243.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.